Hypothesis and TheoryPublished 12 October 2026Treating a systemic disease as a local one: failure points of current pancreatic cancer management and a multimodal, biology-guided framework for redesignPatrick E. SewellFrontiers in Oncologydoi 10.3389/fonc.2026.1941793
OpinionPublished 9 October 2026The N2 dilemma in stage III NSCLC: toward a quantitative framework for trial designLuca Bertolaccini · Monica Casiraghi · Antonio Mazzella · Giorgio Lo Iacono · Lorenzo SpaggiariFrontiers in Oncologydoi 10.3389/fonc.2026.1866606
Original ResearchPublished 7 October 2026Serum GDF15 as a potential biomarker for treatment response and survival in patients with resectable locally advanced gastric cancer undergoing neoadjuvant chemotherapyCan Cao · Shunda Wang · Shikang Ding · Hongyun Huang · Tian Yu · Moxi Chen · Yibin Xie · Jianchun YuFrontiers in Molecular Biosciencesdoi 10.3389/fmolb.2026.1948454
Original ResearchPublished 2 October 2026Clinical and genetic features, surgical management, and longitudinal follow-up in two children with progressive osseous heteroplasiaYuehan Yin · Binshan Zhao · Liying Sun · Wenyao Zhong · Dan Chen · Xiuli Zhao · Wen TianFrontiers in Geneticsdoi 10.3389/fgene.2026.1883125
ReviewPublished 15 July 2026Recurrent retroperitoneal sarcoma: beyond resectability toward a biology-based therapeutic frameworkDorian Yarih Garcia-Ortega · Montiel Jiménez Fuertes · Sergio Damian Quildrian · Nicolas A. Devaud · Javier Martin-BrotoOncology Reviewsdoi 10.3389/or.2026.1846525
